PubRank

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

Clinical Trial ID NCT01056965

PubWeight™ 6.35‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01056965

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983 41.26
2 Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998 26.77
3 Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003 14.03
4 Neurodegenerative diseases target large-scale human brain networks. Neuron 2009 9.69
5 Neurodegenerative tauopathies. Annu Rev Neurosci 2001 9.53
6 PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA. Arch Neurol 1964 9.20
7 Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996 8.82
8 Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007 8.10
9 The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997 6.33
10 Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 2008 4.73
11 Phenotypic correlations in FTDP-17. Neurobiol Aging 2001 3.96
12 Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997 3.77
13 Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003 3.22
14 A clinical rating scale for progressive supranuclear palsy. Brain 2007 2.71
15 Arterial spin-labeled perfusion MRI in basic and clinical neuroscience. Curr Opin Neurol 2009 2.02
16 A femtomolar-acting neuroprotective peptide. J Clin Invest 1996 1.85
17 Dynamic properties of horizontal and vertical eye movements in parkinsonian syndromes. Ann Neurol 1996 1.84
18 Eye movements in parkinsonian syndromes. Ann Neurol 1994 1.84
19 Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 2008 1.82
20 Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2008 1.72
21 Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 1999 1.60
22 Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999 1.60
23 A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008 1.41
24 Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 2003 1.38
25 Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease. Brain 2008 1.36
26 Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 2001 1.30
27 Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 2007 1.30
28 NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009 1.26
29 Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 2007 1.24
30 NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 2005 1.16
31 The diagnosis and course of frontotemporal dementia. Alzheimer Dis Assoc Disord 2007 1.08
32 Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry 2012 1.07
33 Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology 2000 1.05
34 Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr Dis Treat 2014 0.97
35 Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement 2012 0.96
36 A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp Neurol 2008 0.96
37 Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol 2004 0.96
38 Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci 2005 0.95
39 Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia. Expert Rev Neurother 2011 0.91
40 From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J Mol Neurosci 2003 0.88
41 Saccadometry: a new tool for evaluating presymptomatic Huntington patients. Neuroreport 2007 0.88
42 VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J Mol Neurosci 2000 0.88
43 Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept 2004 0.86
44 NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). BMC Neurosci 2008 0.86
45 Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer's disease drug candidates. J Mol Neurosci 2012 0.85
46 Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. Biomed Res Int 2016 0.81
47 A new concept in the pharmacology of neuroprotection. J Mol Neurosci 2000 0.81
48 Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo. J Mol Neurosci 2007 0.79
49 Diagnostic potential of saccadometry in progressive supranuclear palsy. Biomark Med 2007 0.78
50 Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges. J Clin Neurol 2016 0.76
51 Pharmaceutical VIP: prospects and problems. Curr Med Chem 1999 0.76
Next 100